Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Beelen, Dietrich W. [VerfasserIn]   i
 Arnold, Renate [VerfasserIn]   i
 Stelljes, Matthias [VerfasserIn]   i
 Alakel, Nael [VerfasserIn]   i
 Brecht, Arne Jörn [VerfasserIn]   i
 Bug, Gesine [VerfasserIn]   i
 Bunjes, Donald [VerfasserIn]   i
 Faul, Christoph [VerfasserIn]   i
 Finke, Jürgen [VerfasserIn]   i
 Franke, Georg-Nikolaus [VerfasserIn]   i
 Holler, Ernst [VerfasserIn]   i
 Kobbe, Guido [VerfasserIn]   i
 Kröger, Nicolaus [VerfasserIn]   i
 Rösler, Wolf [VerfasserIn]   i
 Scheid, Christoph [VerfasserIn]   i
 Schönland, Stefan [VerfasserIn]   i
 Stadler, Michael [VerfasserIn]   i
 Tischer, Johanna [VerfasserIn]   i
 Wagner-Drouet, Eva [VerfasserIn]   i
 Wendelin, Knut [VerfasserIn]   i
 Brüggemann, Monika [VerfasserIn]   i
 Reiser, Lena [VerfasserIn]   i
 Hoelzer, Dieter [VerfasserIn]   i
 Gökbuget, Nicola [VerfasserIn]   i
Titel:Long-term results of allogeneic stem cell transplantation in adult pH- negative high-risk acute lymphoblastic leukemia
Verf.angabe:Dietrich W. Beelen, Renate Arnold, Matthias Stelljes, Nael Alakel, Arne Brecht, Gesine Bug, Donald Bunjes, Christoph Faul, Jürgen Finke, Georg-Nikolaus Franke, Ernst Holler, Guido Kobbe, Nicolaus Kröger, Wolf Rösler, Christof Scheid, Stefan Schönland, Michael Stadler, Johanna Tischer, Eva Wagner-Drouet, Knut Wendelin, Monika Brüggemann, Lena Reiser, Dieter Hoelzer, Nicola Gökbuget
E-Jahr:2022
Jahr:December 2022
Umfang:9 S.
Fussnoten:Gesehen am 22.05.2023
Titel Quelle:Enthalten in: Transplantation and cellular therapy
Ort Quelle:[Amsterdam] : Elsevier B. V., 2021
Jahr Quelle:2022
Band/Heft Quelle:28(2022), 12, Seite 834-842
ISSN Quelle:2666-6367
Abstract:Allogeneic hematopoietic stem cell transplantation (HCT) is standard treatment for adult high-risk (HR) acute lymphoblastic leukemia (ALL) and contributed to the overall improved outcome. We report a consecutive cohort of prospectively defined HR patients treated on German Multicenter Acute Lymphoblastic Leukemia trials 06/99-07/03 with similar induction/consolidation therapy and HCT in first remission. A total of 542 patients (15-55 years) with BCR-ABL-negative ALL were analyzed. Sixty-seven percent received HCT from matched unrelated donors (MUD) and 32% from matched sibling donors (MSD). The incidence of non-relapse mortality (NRM) was 20% at 5 years. NRM occurred after median 6.6 months; the leading cause (46%) was infection. NRM after MUD decreased from 39% in trial 06/99 to 16% in trial 07/03 (P < .00001). Patient age was the strongest predictor of NRM. The 5-year relapse incidence was 23% using MSD and 25% using MUD. Minimal residual disease (MRD) was the strongest predictor of relapse (45% for molecular failure versus 6% for molecular CR; P < .0001). The median follow-up was 67 months, and the 5-year survival rate was 58%. Age, subtype/high risk feature, MRD status, trial and acute GvHD were significant prognostic factors. We provide a large reference analysis with long follow-up confirming a similar outcome of MSD and MUD HCT and improved NRM for MUD HCT over years. MRD has a strong impact on relapse risk, whereas age was the strongest predictor of NRM. New adapted conditioning strategies should be considered for older patients combined with the goal to reduce the MRD level before stem cell transplantation.
DOI:doi:10.1016/j.jtct.2022.08.024
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.jtct.2022.08.024
 Volltext: https://www.sciencedirect.com/science/article/pii/S2666636722015901
 DOI: https://doi.org/10.1016/j.jtct.2022.08.024
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Adult High-risk ALL
 Allogeneic SCT
 Prospective GMALL Trials
K10plus-PPN:1845886372
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69077810   QR-Code
zum Seitenanfang